The development of several BCR::ABL1 tyrosine kinase inhibitor (TKI) generations, including imatinib, nilotinib, and dasatinib, currently approved as front-line therapy, revolutionized the dismal prognosis of CML patients, offering a life expectancy similar to that of the general population (Gambacorti-Passerini et al., 2011; Viganò et al., 2014; Bower et al., 2016; Hehlmann et al., 2017; Inzoli et al., 2022). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.